Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cellular basis for the mammalian nocturnal-diurnal switch.

Science (New York, N.Y.)·2026
Same author

SMARCA4 Loss Increases RNA Polymerase II Pausing and Elevates R-Loops to Inhibit BRCA1-Mediated Repair in Ovarian Cancer.

Cancer research·2025
Same author

Structural Basis for the Improved RNA Clamping of Amidino-Rocaglates to eIF4A1.

ACS omega·2025
Same author

Protein-RNA interactions mediated by silvestrol-insight into a unique molecular clamp.

Nucleic acids research·2024
Same author

Identification of Rocaglate Acyl Sulfamides as Selective Inhibitors of Glioblastoma Stem Cells.

ACS central science·2024
Same author

Amidino-rocaglates (ADRs), a class of synthetic rocaglates, are potent inhibitors of SARS-CoV-2 replication through inhibition of viral protein synthesis.

Antiviral research·2024

Related Experiment Video

Updated: Mar 9, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K

Developing anti-neoplastic biotherapeutics against eIF4F.

Jutta Steinberger1, Jennifer Chu1, Rayelle Itoua Maïga1

  • 1Department of Biochemistry, McGill University, McIntyre Medical Sciences Building, Rm 810, 3655 Drummond St., Montreal, QC, H3G 1Y6, Canada.

Cellular and Molecular Life Sciences : CMLS
|December 23, 2016
PubMed
Summary
This summary is machine-generated.

Biotherapeutics offer new cancer treatment avenues by targeting eukaryotic initiation factor 4F (eIF4F), a key regulator of protein production. Inhibiting eIF4F shows promise for effective cancer therapies with manageable side effects.

Keywords:
4EBPAntisenseBiotherapeuticsCancer therapeuticsPDCD4Translational controleIF4AeIF4F

More Related Videos

Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

38.3K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.2K

Related Experiment Videos

Last Updated: Mar 9, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.4K
Identification of Protein Interacting Partners Using Tandem Affinity Purification
10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

38.3K
Xenopus laevis as a Model to Identify Translation Impairment
10:24

Xenopus laevis as a Model to Identify Translation Impairment

Published on: September 27, 2015

11.2K

Area of Science:

  • Biotechnology
  • Oncology
  • Molecular Biology

Background:

  • Biotherapeutics, including antibodies and cell therapies, are revolutionizing cancer treatment.
  • Perturbation of translational control, particularly eukaryotic initiation factor 4F (eIF4F) pathways, is a common hallmark of cancer.
  • eIF4F alterations are linked to tumor initiation, progression, and resistance to cancer drugs.

Purpose of the Study:

  • To explore the therapeutic potential of biotherapeutics targeting the eukaryotic initiation factor 4F (eIF4F) complex in cancer treatment.
  • To discuss the opportunities and strategies for developing biological agents aimed at modulating eIF4F activity for oncological applications.

Main Methods:

  • Review of current literature on biotherapeutics in cancer therapy.
  • Analysis of the role of eukaryotic initiation factor 4F (eIF4F) in cancer development and progression.
  • Discussion of the potential of biological agents to target eIF4F pathways.

Main Results:

  • Biotherapeutics represent a significant and impactful sector in pharmaceutical development for cancer.
  • Targeting eukaryotic initiation factor 4F (eIF4F) is a promising strategy due to its association with multiple cancer hallmarks.
  • Systemic suppression of eIF4F appears to be well-tolerated, suggesting a viable therapeutic window.

Conclusions:

  • Biologics offer novel opportunities for targeting eukaryotic initiation factor 4F (eIF4F) in cancer therapy.
  • Modulating eIF4F activity through biotherapeutics holds significant therapeutic promise for various cancers.
  • Further development of targeted biological agents could lead to more effective and tolerable cancer treatments.